199 related articles for article (PubMed ID: 22496148)
1. Treatment-related toxicities in tumor-bearing cats treated with temozolomide alone or in combination with doxorubicin: a pilot assessment.
Gagnon J; Dervisis NG; Kitchell BE
J Feline Med Surg; 2012 Aug; 14(8):560-5. PubMed ID: 22496148
[TBL] [Abstract][Full Text] [Related]
2. Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers.
Awada A; Gil T; Sales F; Dubuisson M; Vereecken P; Klastersky J; Moerman C; de Valeriola D; Piccart MJ
Anticancer Drugs; 2004 Jun; 15(5):499-502. PubMed ID: 15166625
[TBL] [Abstract][Full Text] [Related]
3. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
[TBL] [Abstract][Full Text] [Related]
5. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
[TBL] [Abstract][Full Text] [Related]
6. Hematological toxicity and therapeutic efficacy of lomustine in 20 tumor-bearing cats: critical assessment of a practical dosing regimen.
Fan TM; Kitchell BE; Dhaliwal RS; Jones PD; Hintermeister JG; Paria BC
J Am Anim Hosp Assoc; 2002; 38(4):357-63. PubMed ID: 12118689
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
Lyass O; Hubert A; Gabizon AA
Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours.
Caraglia M; Addeo R; Costanzo R; Montella L; Faiola V; Marra M; Abbruzzese A; Palmieri G; Budillon A; Grillone F; Venuta S; Tagliaferri P; Del Prete S
Cancer Chemother Pharmacol; 2006 Jan; 57(1):34-9. PubMed ID: 16010592
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of low-dose metronomic (LDM) cyclophosphamide toxicity in cats with malignant neoplasia.
Leo C; Stell A; Borrego J; Martinez de Merlo E; Ruess-Melzer K; Lara-Garcia A
J Feline Med Surg; 2014 Aug; 16(8):671-8. PubMed ID: 24423814
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
Warren KE; Aikin AA; Libucha M; Widemann BC; Fox E; Packer RJ; Balis FM
J Clin Oncol; 2005 Oct; 23(30):7646-53. PubMed ID: 16234526
[TBL] [Abstract][Full Text] [Related]
12. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
Jones SF; Gian VG; Greco FA; Miranda FT; Shipley DL; Thompson DS; Hainsworth JD; Toomey MA; Willcutt NT; Burris HA
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):41-5. PubMed ID: 12800606
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
Spiro TP; Liu L; Majka S; Haaga J; Willson JK; Gerson SL
Clin Cancer Res; 2001 Aug; 7(8):2309-17. PubMed ID: 11489806
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23 cats.
Mauldin GN; Matus RE; Patnaik AK; Bond BR; Mooney SC
J Vet Intern Med; 1988; 2(2):60-5. PubMed ID: 3221358
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy.
Ananda S; Nowak AK; Cher L; Dowling A; Brown C; Simes J; Rosenthal MA;
J Clin Neurosci; 2011 Nov; 18(11):1444-8. PubMed ID: 21813279
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical evaluation of carboplatin in tumor-bearing cats: a Veterinary Cooperative Oncology Group study.
Kisseberth WC; Vail DM; Yaissle J; Jeglum KA; Couto CG; Ward H; Khanna C; Obradovich JE
J Vet Intern Med; 2008; 22(1):83-8. PubMed ID: 18289293
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Agarwala SS; Kirkwood JM
Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
[TBL] [Abstract][Full Text] [Related]
18. Hematological toxicity of doxorubicin-containing protocols in dogs with spontaneously occurring malignant tumors.
Ahaus EA; Couto CG; Valerius KD
J Am Anim Hosp Assoc; 2000; 36(5):422-6. PubMed ID: 10997518
[TBL] [Abstract][Full Text] [Related]
19. Management of temozolomide toxicity by nurse practitioners in neuro-oncology.
Zwinkels H; Roon K; Jeurissen FJ; Taphoorn MJ; Hop WC; Vecht CJ
Oncol Nurs Forum; 2009 Mar; 36(2):225-31. PubMed ID: 19273412
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
Ganjoo KN; Cranmer LD; Butrynski JE; Rushing D; Adkins D; Okuno SH; Lorente G; Kroll S; Langmuir VK; Chawla SP
Oncology; 2011; 80(1-2):50-6. PubMed ID: 21625179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
